Journal article
Identification and Treatment of Women with Familial Hypercholesterolemia
Current cardiovascular risk reports, Vol.6(3), pp.196-204
06/01/2012
DOI: 10.1007/s12170-012-0231-7
Abstract
Women with genetic hypercholesterolemias, including familial hypercholesterolemia (FH), are at greatly increased lifetime risk of cardiovascular disease. All women with low-density lipoprotein cholesterol (LDL-C) >= 190 mg/dL after a trial of lifestyle therapy should receive statin therapy. Aggressive risk factor control and complete avoidance of tobacco exposure are required in order to minimize the excess risk conferred by hypercholesterolemia. Most women with FH require high-intensity statin therapy to achieve a > 50% LDL-C reduction for long-term prevention of cardiovascular events. Before starting statins, fibrates, niacin, or ezetimibe, women with FH should be counseled on the potential for birth defects and to discontinue these drugs at least 1-2 months prior to stopping contraception. Cholesterollowering drugs can be resumed once pregnancy and lactation are completed. All women should have a fasting lipid panel performed by age 20 years. The children and other first-degree relatives of women with LDL-C >= 190 mg/dL should be screened for FH.
Details
- Title: Subtitle
- Identification and Treatment of Women with Familial Hypercholesterolemia
- Creators
- Jennifer G. Robinson - Univ Iowa, Prevent Intervent Ctr, Dept Epidemiol, 105 River St S455 CPHB, Iowa City, IA 52242 USA
- Resource Type
- Journal article
- Publication Details
- Current cardiovascular risk reports, Vol.6(3), pp.196-204
- Publisher
- Springer Nature
- DOI
- 10.1007/s12170-012-0231-7
- ISSN
- 1932-9520
- eISSN
- 1932-9563
- Number of pages
- 9
- Language
- English
- Date published
- 06/01/2012
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984364436702771
Metrics
4 Record Views